Bernard Rosenberg
Psychiatry · Spring, TXNPI 1568519601
Payments from drug & device makers
Across 1,353 payments — averaging $47.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$27K
- Supernus Pharmaceuticals, Inc.$15K
- AbbVie$6K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $11K from 36 others
What the payments were for
- Speaking & faculty fees$41,57565%
- Travel & lodging$1,6623%
- Food & beverage$20,82732%
- Education$3701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$17,042
- QELBREE$12,249
- JORNAY PM$8,921
- VRAYLAR$3,885
- Equetro$266
- Adzenys XR-ODT$103
How this compares
$64,435 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 58 | $471,940 |
| Austedo XrDeutetrabenazine | 37 | $223,814 |
| Invega TrinzaPaliperidone Palmitate | 12 | $116,371 |
| Abilify MaintenaAripiprazole | 37 | $97,164 |
| CaplytaLumateperone Tosylate | 27 | $48,059 |
| RexultiBrexpiprazole | 19 | $27,484 |
| VyvanseLisdexamfetamine Dimesylate | 70 | $26,071 |
| VraylarCariprazine Hcl | 13 | $18,998 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,359 |
| Lisdexamfetamine Dimesylate | 74 | $16,413 |
| Bupropion XlBupropion Hcl | 214 | $12,918 |
| TrintellixVortioxetine Hydrobromide | 21 | $11,959 |
| Aripiprazole | 99 | $7,255 |
| Paliperidone ErPaliperidone | 23 | $6,778 |
| TopamaxTopiramate | 12 | $6,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,600 | $471,94058 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,552 | $223,81437 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,583 | $124,64856 claims |
| Johnson & JohnsonInvega Trinza | $621 | $116,37112 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,766 | $48,05927 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $673 | $38,02991 claims |
| AbbVieVraylar, Synthroid | $5,600 | $20,68426 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $217 | $17,35911 claims |
| Almatica Pharma LLCSertraline Hcl | $589 | $1,875126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Spring
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.